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Summary
Progressive memory loss and cognitive dysfunction
are the hallmark clinical features of Alzheimer’s dis-
ease (AD). Identifying the molecular triggers for the
onset of AD-related cognitive decline presently re-
quires the use of suitable animal models, such as the
3xTg-AD mice, which develop both amyloid and tan-
gle pathology. Here, we characterize the onset of
learning and memory deficits in this model. We report
that 2-month-old, prepathologic mice are cognitively
unimpaired. The earliest cognitive impairment mani-
fests at 4 months as a deficit in long-term retention
and correlates with the accumulation of intraneuronal
A in the hippocampus and amygdala. Plaque or tan-
gle pathology is not apparent at this age, suggesting
that they contribute to cognitive dysfunction at later
time points. Clearance of the intraneuronal A pathol-
ogy by immunotherapy rescues the early cognitive
deficits on a hippocampal-dependent task. Reemer-
gence of the A pathology again leads to cognitive
deficits. This study strongly implicates intraneuronal
A in the onset of cognitive dysfunction.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder and the most common cause of de-
mentia worldwide. Episodic memory, which is defined
as the ability to recall past experiences, is disrupted in
AD and typically appears to be the first cognitive do-
main that is impacted in AD patients (Welsh et al., 1992;
Artero et al., 2003). As the disease progresses, other
cognitive deficits manifest, particularly in attention and
executive functions, semantic memory, language, and
spatial orientation (Perry and Hodges, 1999; Lambon
Ralph et al., 2003). Criteria for the clinical diagnosis of
AD are achieved once cognitive deficits become se-
vere enough to disrupt normal social and occupa-
tional function.
The molecular, cellular, and pathological changes
that trigger the onset of cognitive decline in the AD brain
are presently unknown and are an intractable problem
to address in humans until brain imaging achieves
higher spatial and temporal resolution. Hence, animal
models remain invaluable tools for identifying the mo-
lecular markers that trigger the onset of AD-related
cognitive decline. Toward this end, our lab generated
a triple-transgenic model of AD (3xTg-AD) that mimics*Correspondence: laferla@uci.edumany critical aspects of AD neuropathology: (1) amy-
loid plaques and neurofibrillary pathology develop in
a hierarchical manner in AD-relevant brain regions,
mainly the hippocampus, cortex, and amygdala; (2)
plaque pathology precedes tangle formation, and plaques
consist of the longer, more amyloidogenic Aβ42; (3) the
pattern of conformational and phosphorylation changes
that the tau protein undergoes parallels the sequence
in the human AD brain; (4) the 3xTg-AD mice show se-
lective loss of nicotinic α7 receptors in the hippocam-
pus and cortex (Oddo et al., 2003, 2005). These mice
also develop dysfunction in synaptic plasticity, includ-
ing deficits in LTP and paired-pulse facilitation, in con-
junction with the early, intraneuronal accumulation of
Aβ (Oddo et al., 2003).
It is presently unclear how the hallmark features of
AD neuropathology, plaques and tangles, relate to the
emergence of cognitive impairments. It is well estab-
lished that the number of plaques does not correlate
with cognitive performance in AD patients (Arriagada et
al., 1992; Samuel et al., 1994). In contrast, it appears
that total Aβ load is a better measure (Cummings and
Cotman, 1995). Although the number of tangles is a
better predictive measure of overall cognitive function
in humans with a clinical AD diagnosis (McKee et al.,
1991), tangles still do not present a reliable biomarker
for the onset of early cognitive changes. Synaptic loss
appears to be the best correlate of the cognitive dys-
function in AD patients (Terry et al., 1991), although the
trigger underlying the synaptic pathology is not yet re-
solved. The human studies are corroborated by data
from various transgenic mouse models of AD in which
it appears that cognitive impairments emerge prior to
any overt neuropathology and correlate poorly with
plaque number (Mucke et al., 1994; Hsiao, 1995; Moe-
chars et al., 1999; Dodart et al., 2002). The sum of these
studies, however, does not rule out an early, pathogenic
form of amyloid as the trigger for the onset of cognitive
dysfunction in both humans and transgenic mice.
In this study, we sought to define the molecular trig-
ger for the onset of cognitive decline in a transgenic
model of AD. We examined 3xTg-AD mice for learning
and memory deficits in spatial reference and contextual
learning tasks, which involve the hippocampus and
also the amygdala, respectively (Sutherland and Mc-
Donald, 1990; Davis, 1992; Nakazawa et al., 2004). Both
cross-sectional and longitudinal analyses were per-
formed, allowing us to track the long-term performance
of each mouse and compare it to age- and sex-
matched naive mice at each time point. We report that
prepathologic 3xTg-AD mice perform comparably to
age-matched nontransgenic (NonTg) mice. We find that
the initial cognitive impairments manifest as a retention
deficit, as the 3xTg-AD mice effectively learn both tasks
but fail to retain essential information from day to day.
These findings parallel the changes reported in humans
with mild cognitive impairment (MCI), which involves a
deterioration in episodic memory with the maintenance
of other cognitive processes (Grundman et al., 2004).
We further show that the retention deficits correlate
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Aance of intraneuronal Aβ rescues the cognitive impair-
ments. We further show that reemergence of the Aβ A
apathology in antibody-treated mice is again associated
with cognitive deficits. To our knowledge, this is the (
ffirst report to identify a pathophysiologic role for intra-




fTo elucidate the molecular determinants that trigger the
aonset of learning and memory deficits, we evaluated
mthe following groups of mice: (1) 3xTg-AD homozygous
dmice (3xTg-AD-H); (2) 3xTg-AD hemizygous mice (3xTg-
iAD-h); (3) presenilin-1 M146V knockin mice (PS1 KI),
lthe line from which the 3xTg-AD mice were derived;
aand (4) NonTg mice (Table 1). Each group was tested at
t2 months and again at 6 months of age. In addition,
26-month-old naive mice were also evaluated to control
tfor “savings” from previous exposure to the behavioral
atest and to compare performance between the naive
aand experienced groups. Because the amyloid and
2neurofibrillary pathology is predominantly confined to
tthe hippocampus, cortex and amygdala, learning and
amemory were evaluated using the spatial reference ver-
ssion of the Morris water maze (MWM) and inhibitory
(avoidance (IA), which are tasks that are highly depen-
dent on the hippocampus and the hippocampus and
tamygdala, respectively (Sutherland and McDonald, 1990;
3Davis, 1992; Nakazawa et al., 2004). The cued platform
hversion of the MWM (herein referred to as cued MWM)
fwas also utilized to control for visual ability and intact
striatal-mediated learning. bTable 1. Genotype, Group, and Number of Mice Used in Each Study
Genotype Behavioral Test Group Number of Animals
3xTg-AD-H MWM experienced 12 (6M, 6F)
naive 14 (7M, 7F)
3xTg-AD-h MWM experienced 16 (5M, 11F)
naive 11 (5M, 6F)
PS1-KI MWM experienced 13 (7M, 6F)
naive 11 (6M, 5F)
NonTg MWM experienced 15 (7M, 8F)
naive 13 (7M, 6F)
3xTg-AD-H IA experienced 14 (7M, 7F)
naive 15 (8M, 7F)
3xTg-AD-h IA experienced 16 (9M, 7F)
naive 14 (7M, 7F)
PS1-KI IA experienced 13 (6M, 7F)
naive 11 (5M, 6F)
NonTg IA experienced 18 (8M, 10F)
naive 12 (6M, 6F)
3xTg-AD-H MWM/IA 4 month testing 8 (6M, 2F)
3xTg-AD-h MWM/IA 4 month testing 8 (6M, 2F)
NonTg MWM/IA 4 month testing 7 (4M, 3F)
3xTg-AD-H MWM/IA 4 month 1560 (7 days) 8 (4M, 4F)
4 month 1560 (30 days) 6 (3M, 3F)
4 month PBS (7 days) 5 (3M, 2F)
NonTg MWM/IA 4 month 1560 (7 days) 5 (2M, 3F)
4 month PBS (7 days) 5 (2M, 3F)
Hemizygous and homozygous mice are indicated as 3xTg-AD-h and 3xTg-AD-H, respectively. “Experienced” mice were tested at 2 months
and again at 6 months, whereas “naive” mice were tested only at 6 months. Experienced and naive mice in the first study were trained and
tested on only one task. Four-month-old mice (in both behavior only and behavior + surgery experiments) were all naive and were trained
and tested on both Morris water maze (MWM) and inhibitory avoidance (IA).oung, Prepathologic 3xTg-AD Mice
re Cognitively Normal
t 2 months of age, no overt Aβ or tau pathology is
pparent in any brain region of the 3xTg-AD mice
Oddo et al., 2003). Nonetheless, analysis of cognitive
unction at this time point is crucial to determine if the
ice are born with learning and memory impairments
r if they manifest in a progressive, age-related manner.
ur analysis indicated that all groups of mice had intact
patial learning at this time point (Figure 1A; p = 0.589
or overall acquisition for all genotypes). Therefore,
cquisition for spatial learning is not impaired at 2
onths of age in 3xTg-AD-H or 3xTg-AD-h mice. In ad-
ition, all groups acquired the cued MWM task equally,
ndicating intact visual abilities and striatal-mediated
earning (Figure 1B; p = 0.762 for overall acquisition for
ll genotypes). Furthermore, no deficits in either short-
erm or long-term memory were observed in the 1.5 and
4 hr spatial reference memory probe trials; we find that
he 3xTg-AD mice performed as well as NonTg mice on
ll probe measures (Figures 1C–1E; p > 0.05 for
ll measures). We also assessed the memory of the
-month-old groups following contextual fear condi-
ioning, which is highly dependent on hippocampal
nd amygdala function. Two-month-old 3xTg-AD mice
howed no impairment in memory for contextual fear
Figure 1F; p = 0.855 for retention for all genotypes).
Based on their performance on the MWM and con-
extual fear conditioning, we conclude that 2-month-old
xTg-AD mice show normal learning and memory on
ippocampal- and amygdala-dependent tasks. This
inding is critical, as it illustrates that the mice are not
orn with any cognitive impairments. Consequently,
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Mice Are Cognitively Normal
The 3xTg-AD mice were evaluated on both
spatial reference and contextual learning
paradigms and compared to PS1-KI and
NonTg mice. Asterisks denote differences
with respect to NonTg mice at a p < 0.05
significance level. Error bars indicate SEM.
(A) All groups of mice learn the MWM task at
2 months of age. Mice were trained on the
spatial reference version of the MWM task
and were required to swim to a hidden plat-
form submerged in a tank located in a room
with several large, visual cues. 3xTg-AD-H
and 3xTg-AD-h mice show no impairment
during acquisition on the MWM task. (B–E)
Short- and long-term memory is intact at 2
months of age. During the 1.5 and 24 hr
probe trials with the platform removed, both
homozygous and hemizygous 2-month-old
3xTg-AD mice showed similar latencies to
cross the platform location (C), number of
platform location crosses (D), and time spent
in the opposite quadrant (E) as compared to
NonTg and PS1-KI mice. There were also no
differences between genotypes on the visi-
ble platform (cued) training in the MWM (B).
(F) Contextual learning and memory is unim-
paired in 3xTg-AD mice at 2 months of age.
Probe trials were conducted 1.5 and 24 hr
after IA training, and both homozygous and
hemizygous 2-month-old 3xTg-AD mice per-
formed comparably to NonTg and PS1-KI
mice with regards to retention for contex-
tual fear.any cognitive dysfunction that manifests in the 3xTg-
AD mice will be age dependent and due to the trans-
gene products or their derivatives.
Early Cognitive Impairments Manifest as Retention,
Not Learning, Deficits
At 6 months of age, 3xTg-AD-H mice are neuropatho-
logically characterized by diffuse amyloid plaques in
the neocortex, and intraneuronal Aβ buildup in pyrami-
dal neurons of the hippocampus, cortex, and amygdala
(Oddo et al., 2003; Figures 2A and 2B). 3xTg-AD-h mice,
in contrast, exhibit only intraneuronal Aβ pathology in
the hippocampus, cortex, and amygdala (Oddo et al.,
2003; Figures 2C and 2D).
At this age, all groups of mice were able to learn the
MWM task (Figure 3A; p < 0.001 for overall acquisition
for all genotypes). However, 6-month-old 3xTg-AD-H
mice required 6 days of training to reach criterion (es-
cape latency of <20 s) compared to 3 days at 2 months
of age. It is critical to note that 1.5 and 24 hr probe
trials were conducted at 3 days, when all but the 3xTg-
AD-H mice had reached criterion, thereby controlling
for overlearning in these groups. Importantly, the in-
creased training for the homozygous mice was specifi-
cally due to deficits in spatial reference learning or
memory, as there were no differences among geno-types on acquisition of the cued MWM task (p = 0.644
for overall acquisition for all genotypes; Figure 3B).
Based on these findings, it is clear that the homozy-
gous mice are able to learn the task but require more
training compared to the other genotypes tested. Two
explanations could account for this observation: either
(1) the homozygous mice have a learning deficit that
consequently requires more training trials to reach cri-
terion, or (2) they have no deficit in learning but are
unable to retain the learned information from day to
day. To distinguish between these two possibilities, we
analyzed the performance of the 3xTg-AD-H mice on a
“trial-by-trial” basis. Notably, we found that the 3xTg-
AD-H had significantly longer escape latencies at the
first trial of every day compared to the last trial the pre-
vious day (Figure 3C; p < 0.001 for each Student’s t test
comparison). In other words, the poorer performance
of the 3xTg-AD-H mice was caused by a day-to-day
retention impairment. This effect was also apparent in
hemizygous mice, but did not appear to affect their
overall learning (Figures 3A and 3C). In contrast, 2-month-
old 3xTg-AD mice showed no such retention deficits
in a trial-by-trial analysis (data not shown). These data
indicate that the 6-month-old 3xTg-AD mice have diffi-
culty retaining the information from day to day but are






















pFigure 2. 3xTg-AD Mice Develop Intraneuronal and Extracellular Aβ
uPathology at 6 Months of Age
a(A–D) Comparison of Aβ pathology in hemizygous versus homozy-
6gous mice. 3xTg-AD homozygous (A and B) and hemizygous (C
and D) mice develop intracellular accumulation of Aβ in the cortex 2
and hippocampus (A and C) and amygdala (B and D). At this age, m
there is also some extracellular Aβ deposition in homozygous mice e
(arrows indicate extracellular Aβ in the cortex in [A]).
e
oTwo sets of probe trials were conducted to assess
mthe memory of the groups once they had reached crite-
trion. For all groups except the 3xTg-AD-H, criterion
fwas reached after 3 days of training, and thus probe
etrials were conducted for all groups at 1.5 and 24 hr
eposttraining on days 3 and 4, and again on days 6–7,
0when the 3xTg-AD-H mice had reached criterion (Fig-
lures 3D and 3E). Both short-term and long-term spatial
sreference memory (1.5 and 24 hr posttraining, respec-
ntively) were impaired in the 3xTg-AD-H mice, as they
cperformed significantly worse than NonTg mice on all
iprobe measures at both 3-4 days and 6–7 days post-
training (Figures 3D and 3E; p < 0.02 for all compari-
3sons; time in opposite quadrant not shown). It is per-
ehaps not surprising that the 3xTg-AD-H mice were
mimpaired at the first block of probe trials, as they had
hnot yet demonstrated that they had learned the task
tand would therefore not exhibit memory for the plat-
hform location. However, when the 3xTg-AD-H mice had
creached criterion for learning the task within a block of
ltrials by day 6, they still demonstrated impairments in
Cretention when given a probe trial 1.5 or 24 hr later.
lNotably, we also found a genotype-specific effect, as
2the 3xTg-AD-h mice displayed impaired long-term but
Anot short-term retention for spatial reference memory
d(Figures 3C and 3D; p < 0.05 for all comparisons to
cNonTg mice). Taken together, these results demon-
gstrate that retention deficits are the first impairments to
memerge in the 3xTg-AD mice.
Because the 6-month-old mice in the longitudinal
study were exposed to the MWM task for the second O
wtime (i.e., at 2 and 6 months of age), naive mice were
also tested in parallel to assess any effect of previous T
experience with the task (Table 1). We found that thereere no differences between experienced and naive
ice on any of the measures tested at 6 months of age,
ndicating that previous exposure to the MWM task did
ot improve overall acquisition or retention during any
f the probe trials (Figure 3). However, it is important to
ote that both naive and experienced 3xTg-AD-H mice
ere impaired on all probe trial measures at both 1.5
nd 24 hr after training, and hemizygous mice exhibited
mpairments in long-term memory (Figures 3C and 3D).
herefore, based on these analyses, we conclude that
here is a genotype effect, with both hemizygous and
omozygous 3xTg-AD mice showing retention deficits;
t 6 months, hemizygous mice are deficient in long-
erm memory, whereas homozygous mice are deficient
n both long-term and short-term memory in accord
ith the more severe neuropathology that is present in
he homozygous versus hemizygous mice at this age.
ontextual Fear Deficits
ecause 6-month-old 3xTg-AD-H mice show intraneu-
onal Aβ pathology in the amygdala, we evaluated their
erformance on passive IA, which is a form of context-
al learning that is dependent on the amygdala as well
s the hippocampus. All genotypes of experienced
-month-old mice (i.e., previously trained and tested at
months), retained contextual fear upon retraining at 6
onths (Figure 3F; p < 0.001; Student’s t test; experi-
nced versus naive latencies). Consequently, previous
xposure to the IA task, even 4 months prior, improved
verall retention for the contextual fear.
Notably, both experienced and naive 3xTg-AD-H
ice showed significantly impaired short- and long-
erm retention for contextual fear (Figure 3F; p < 0.05
or both Scheffe comparisons to NonTg mice), whereas
xperienced and naive hemizygous 3xTg-AD mice only
xhibited impaired long-term retention (Figure 3F; p <
.05 compared to NonTg mice). These results were not
ikely due to differing sensitivity to shock, as all mice
howed equal jump responses upon shock onset (data
ot shown). Therefore, based on these analyses, we
onclude that contextual fear conditioning is impaired
n 6-month-old 3xTg-AD mice.
Based on the above data, it is clear that 6-month-old
xTg-AD mice show retention deficits in spatial refer-
nce and contextual fear memory, with hemizygous
ice showing deficits in long-term retention only and
omozygous mice displaying impaired short and long-
erm retention. At this age, homozygous 3xTg-AD mice
ave no apparent tangle pathology, but there are extra-
ellular Aβ plaques in the cerebral cortex and intracellu-
ar Aβ accumulation within pyramidal neurons of the
A1 region of the hippocampus and also within baso-
ateral amygdala and cortical neurons (Figures 2A and
B). Hemizygous 3xTg-AD mice have only intraneuronal
β pathology in the hippocampus, cortex, and amyg-
ala (Figures 2C and 2D). However, the age at which
ognitive decline begins and the precise molecular trig-
er(s) of cognitive dysfunction in the 3xTg-AD mice re-
ain unknown.
nset of Long-Term Retention Deficits Correlates
ith Intraneuronal A
he finding of a genotype-specific effect on memory inthe 3xTg-AD mice (i.e., long-term memory but not
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679Figure 3. The Earliest Cognitive Impairment
Manifests as a Retention, Not Learning, Defi-
cit in the 3xTg-AD Mice
We compared the performance of both “ex-
perienced” (i.e., having been already trained
and tested at 2 months of age) and “naive”
3xTg-AD mice to experienced or naive
NonTg and PS1-KI mice. Asterisks denote
significant differences with respect to NonTg
mice at a p < 0.05 level. Error bars indicate
SEM. (A) 3xTg-AD homozygous mice require
more training to reach criterion in the MWM.
At 6 months of age, both experienced and
naive 3xTg-AD homozygous mice require
more trials to reach criterion (escape latency
<20 s) as compared to all other genotypes
tested. (B) 3xTg-AD hemizygous and homo-
zygous mice show no impairments on the
cued MWM (naive groups not shown). (C)
3xTg-AD mice fail to retain information from
day to day. Analysis of the data on a trial-by-
trial basis reveals that the increased training
required during acquisition represents a re-
tention, not learning, deficit, as the 3xTg-AD
homozygous mice learn the task equally well
within a day’s worth of trials but fail to retain
the location of the platform between daily
training blocks (cf. the 3xTg-AD-H latencies
on the first trial of each day and the last trial
on the previous day). This was true for both
experienced and naive mice (for clarity of the
graph, naive group data are not shown). (D
and E) At 6 months, 3xTg-AD-h mice show
long-term retention deficits, whereas 3xTg-
AD-H mice show both short- and long-term
retention deficits. NonTg, PS1, and 3xTg-
AD-h mice reached criterion by day 3 of
training, but homozygous mice did not reach
criterion until day 6. Therefore, probe trials
were conducted at days 3–4 and again at
days 6–7. At both 1.5 and 24 hr probe trials
with the platform removed, both naive and
experienced 3xTg-AD-H mice show memory
retention impairments on the latency to
cross the platform location (D), number of platform location crosses (E), and time spent in the opposite quadrant (data not shown). However,
both naive and experienced hemizygous mice were only impaired at 24 hr on all probe measures, indicative of a long-term memory retention
deficit. There were no differences between NonTg, PS1, or 3xTg-AD-h performance on the first set of probe trials (days 3–4) and the second
set of probe trials (days 6–7), indicating that their performance on days 6–7 was not due to overlearning. However, as expected, 3xTg-AD-H
mice improved significantly between the first set of probe trials and the second set of probe trials (p < 0.02 for comparisons between
corresponding probe trials on days 3–4 and days 6–7). (F) 3xTg-AD-H and 3xTg-AD-h mice show impaired contextual memory. All experienced
groups of all genotypes displayed retention for IA training 4 months prior, though homozygous mice show a trend toward reduced latencies
during retraining as compared to NonTg mice (p = 0.07). However, 1.5 and 24 hr after additional IA training, both naive and experienced 3xTg-
AD homozygous mice show impaired memory for contextual fear conditioning as compared to NonTg mice. 3xTg-AD-h mice show memory
impairment only at 24 hr posttraining, again indicative of a retention deficit. This was not due to differences in sensitivity to the shock, as all
mice had similar jump responses upon shock administration.short-term memory is impaired in the hemizygous mice,
whereas both domains are impacted in the homozy-
gous mice) indicated a dose-dependent effect of the
pathology buildup on cognitive function. Consequently,
we additionally monitored the performance of 4-month-
old mice on spatial reference memory (MWM) and
contextual fear conditioning (IA; Table 1). We hypothe-
sized that this time point would allow us to more pre-
cisely determine when cognitive impairments first man-
ifest and the molecular pathological correlates that
underlie this effect.
With regards to learning, we found that 4-month-old
naive 3xTg-AD-H mice performed as well as naive
hemizygous and NonTg mice at acquiring the location
of the hidden platform in the MWM task (Figure 4A;note that PS1KI mice were not tested, as they showed
no behavioral deficits at 2 or 6 months of age). There-
fore, 3xTg-AD-H mice do not have any acquisition defi-
cits at this age, whereas at 6 months of age their perfor-
mance was worse than the other genotypes and they
required more trials to reach criterion (cf. Figure 3A with
Figure 4A).
We further analyzed the performance of the mice by
trial, which revealed that 4-month-old 3xTg-AD-H mice
show retention deficits from day to day during training,
with significant differences between the first trial of
each day and the last trial on the previous day (Figure
4B; p < 0.05 for each comparison). Indeed, this reten-
tion deficit was also apparent during the probe trials:
at the 1.5 hr probe, 4-month-old 3xTg-AD-H mice dis-
Neuron
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Deficits Correlates with Intraneuronal Aβ
(A and B) 3xTg-AD mice show no acquisition
impairments on the MWM at 4 months (A).
However, when broken down into a trial-by-
trial analysis, 3xTg-AD-H mice displayed sig-
nificant retention deficits between the first
training trial on each day and the last trial on
the previous day (B). Asterisks denote sig-
nificance as compared to NonTg mice at a
p < 0.05 level. Error bars indicate SEM. (C–
E) 3xTg-AD-H mice first develop deficits in
long-term retention. 3xTg-AD-H mice had no
differences in any probe measures at 1.5 hr
(C–E) but at the 24 hr probe test had signifi-
cantly longer latencies to cross the platform
location (C) and had fewer platform location
crosses (D) as compared to both hemizy-
gous and NonTg mice. 3xTg-AD-H mice did
not spend significantly more time in the op-
posite quadrant (E), indicating retention for
general but not specific platform location. (F)
Differences on the MWM were not due to
deficits in visual navigation or in swimming
ability, as no differences emerged between
any genotypes on the cued MWM task. (G)
Retention deficits were also present in
contextual fear memory in 3xTg-AD mice. At
the 1.5 hr probe trial, all groups showed sim-
ilar step-through latencies, but at 24 hr 3xTg-
AD-H mice showed significantly shorter step-
through latencies as compared to NonTg
and hemizygous mice. (H–J) At 4 months of
age, 3xTg-AD-H mice display intraneuronal
Aβ pathology in the hippocampus (H), cortex
(I), and amygdala (J) but no extracellular Aβ
deposition. (K) Confocal microscopic ana-
lysis of intraneuronal Aβ accumulation in
4-month-old 3xTg-AD-H mice shows that Aβ
accumulates in a diffuse pattern throughout
the cytoplasm of hippocampal (shown here),
cortical, and amygdala neurons. Green, 6E10
staining; blue, nuclear TOTO staining. Mag-
nification, 100×.played similar performance to NonTg mice on all probe d
rmeasures (p > 0.05 for both measures), but during the
24 hr probe trial, homozygous mice had slower laten-
pcies to cross platform location (Figure 4C; p < 0.02) and
had fewer platform location crosses (Figure 4D; p < (
t0.05) than NonTg mice. However, it is clear that some
indices of retention are intact in 4-month-old mice at i
rboth 1.5 and 24 hr, as homozygous mice spend similar
amounts of time in the opposite quadrant during both i
Uprobe trials, indicating that they may remember the cor-
rect general but not specific location of the platform d
4(Figure 4E). Importantly, 4-month-old 3xTg-AD-H mice
are also unimpaired on acquisition of the cued MWM s
dtask (Figure 4F). 3xTg-AD-h mice show no apparent
spatial reference or visual deficits at 4 months of age. i
pA similar pattern in retention for contextual learning
was apparent in 4-month-old 3xTg-AD-H mice during o
mIA testing. These mice, which were all naive, exhibited
normal retention for contextual fear at 1.5 hr posttrain-
eing, but significantly reduced latency to enter the dark
compartment during the 24 hr probe trial, indicative of oecreased memory retention for fear-associated envi-
onments (Figure 4G; p < 0.05).
At this age, 3xTg-AD-H mice show intraneuronal Aβ
athology in the hippocampus, cortex, and amygdala
Figures 4H–4J, respectively) but do not contain any ex-
racellular Aβ deposits. In order to confirm that the Aβ
mmunoreactivity was predominantly present intraneu-
onally, and not an artifact of diffuse extracellular stain-
ng, we analyzed sections by confocal microscopy.
sing this technique, it is clear that Aβ accumulates
iffusely throughout the neuronal cytoplasm (Figure
K). This pattern of intraneuronal Aβ staining was con-
istent throughout all hippocampal, cortical, and amyg-
ala sections examined; no diffuse extracellular stain-
ng was noted. Therefore, we conclude that there is
rominent intraneuronal Aβ accumulation at 4 months
f age and that it precedes extracellular plaque for-
ation.
Because the only neuropathological change appar-
nt in the 4-month-old 3xTg-AD-H mice is the presence
f Aβ-immunoreactive neurons in the cerebral cortex
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681hippocampus, and amygdala, we conclude that intra-
neuronal accumulation of Aβ may lead to neuronal dys-
function and may trigger cognitive impairments in both
spatial and contextual learning.
Clearance of Intraneuronal A Pathology
by Immunotherapy Reverses Early
Cognitive Impairment on the MWM
Because the onset of the cognitive impairments in the
3xTg-AD mice correlates with the occurrence of intra-
neuronal Aβ, we next sought to determine whether its
clearance from neurons would rescue the early cogni-
tive deficits. We previously demonstrated that intrahip-
pocampal administration of an anti-Aβ antibody effec-
tively removes not only extracellular Aβ deposits but
also intraneuronal Aβ pathology (Oddo et al., 2004). Be-
cause of the highly focal nature of the clearance medi-
ated by the intrahippocampal injection, we changed
paradigms and administered Aβ antibodies into the
third ventricle.
Four-month-old NonTg and 3xTg-AD-H mice were
given intracerebroventricular (i.c.v.) injections of the
anti-Aβ antibody 1560 or PBS vehicle and trained and
tested on MWM and IA 1 week later (Table 1). As ex-
pected, i.c.v. injections led to bilateral clearance of the
pathology in selective brain regions (Figures 5A and
5F). We found that, in the 3xTg-AD mice trained and
tested 7 days postinjection, intraneuronal Aβ pathology
was reduced by 86% from both hippocampi relative to
age-matched PBS-treated 3xTg-AD mice (Figures 5A–
5C). This reduction in intraneuronal Aβ staining was not
due to a decrease in full-length APP, as no differences
were noted between PBS and anti-Aβ antibody injec-
tions with 22C11 staining (Figures 5D and 5E). Although
there is no apparent staining for Aβ40 in 4-month-old
3xTg-AD mice (data not shown), there is intraneuronal
accumulation of Aβ42 within the hippocampus, cortex,
and amygdala (Figure 5F). Following i.c.v. injection of
the anti-Aβ antibody, there was a marked reduction of
hippocampal intraneuronal Aβ42 (Figures 5F and 5G).
There was also a clearance of cortical intraneuronal Aβ
pathology, predominantly in regions adjacent to sen-
sory and motor cortices and, to various extents, ex-
tending into temporal cortical regions (data not shown).
Notably, we found that the pathology in the amygdala
was not cleared (Figures 5H and 5I). This is perhaps not
so surprising, as the antibody was administered into
the third ventricle, which is dorsally located in the brain,
whereas the amygdala is a ventrally located structure.
Therefore, the lack of clearance in the amygdala may
be due to its relatively distal location or due to insuffi-
cient penetration of the antibody into the amygdala pa-
renchyma.
Biochemical analysis of Aβ levels by ELISA indicated
that levels of detergent-insoluble Aβ42, the form of Aβ
that readily forms aggregates, increase significantly be-
tween 2 and 4 months of age in the 3xTg-AD mice (Fig-
ure 6A). Previous studies from our laboratory indicate
that at 2 months the Aβ levels in the 3xTg-AD mice are
equivalent to NonTg levels, and whereas NonTg Aβ
levels do not increase with age, the levels in the 3xTg-
AD mice steadily increase with age (Oddo et al., 2003).
Although the focal nature of the antibody clearanceprecluded biochemical analysis of Aβ levels from immu-
nized mice, confocal microscopy indicated that the Aβ
pathology in PBS-injected 3xTg-AD mice was similar to
untreated mice, in that it included diffuse cytoplasmic
staining (cf. Figures 6B and 4K). However, in 3xTg-AD
mice receiving anti-Aβ antibody 7 days prior to behav-
ioral training and testing, there was a complete ab-
sence of cytoplasmic Aβ staining (Figure 6C). Extensive
analysis of the confocal as well as the light microscopy
images failed to detect any extracellular Aβ deposition.
Because we could reverse the intraneuronal pathol-
ogy with Aβ immunotherapy, we were positioned to ex-
amine the contribution of intraneuronal Aβ to memory
impairments in a task that involves the hippocampus
(MWM) and a task that relies on an intact amygdala as
well (IA). In other words, we could determine if clear-
ance of the Aβ pathology from the hippocampus res-
cued the deficits on MWM, whereas no rescue would
be expected for IA, as the pathology was unaffected by
treatment in this region.
Injection of either PBS or the anti-Aβ antibody did not
appear to disrupt learning, as the acquisition curves
were quite similar between all groups for both NonTg
and 3xTg-AD mice (Figure 7A). However, analysis of the
data on a trial-by-trial basis reveals a profound effect.
First, note that the performance of the NonTg mice im-
proves with each trial, and this information is retained
from day to day (whether PBS or the anti-Aβ antibody
is administered; Figure 7A). Second, 3xTg-AD mice re-
ceiving PBS 7 days prior (3xTg-AD PBS) continue to
show retention deficits (Figures 7B–7D; cf. Figure 4B;
p < 0.05; Student’s t test). Third, and quite remarkably,
we found that the retention deficits were obliterated in
the 3xTg-AD mice treated with the anti-Aβ antibody and
trained and tested 7 days postinjection (3xTg-AD 1560
7 day; Figures 7B–7D; p > 0.05 for all measures). These
data indicate that removal of intraneuronal Aβ pathol-
ogy in the 3xTg-AD mice is sufficient to reverse early
retention deficits. No differences emerged between
genotypes on the cued MWM acquisition (Figure 7F;
p > 0.05).
Because the i.c.v.-based immunotherapy selectively
cleared the pathology from the hippocampus but not
from the amygdala, we anticipated that the retention
deficits in contextual fear conditioning would not be
rescued. Indeed, both 3xTg-AD 1560- and PBS-treated
mice showed impaired retention for contextual fear
conditioning at 24 hr. Note that 4-month-old mice show
no deficits on the 1.5 hr probe trials, and this was also
true for mice in the i.c.v. injection study. This lack of
recovery of the retention deficit on IA is particularly sig-
nificant, as pathology in the amygdala was not affected
by i.c.v. administration of the anti-Aβ antibody (Figures
5H and 5I), and the cognitive deficits in a task that relies
not only on an intact hippocampus but also on an intact
amygdala were not rescued by the antibody treatment.
In contrast, retention deficits on the hippocampal-
dependent MWM task were completely reversed fol-
lowing antibody-mediated hippocampal intraneuronal
Aβ clearance. These findings strongly argue for the role
of intraneuronal Aβ accumulation as the trigger for the
onset of early retention deficits in the 3xTg-AD mice.
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The anti-Aβ antibody 1560 was administered into the third ventricle of 4-month-old 3xTg-AD-H mice (n = 8). (A and B) i.c.v. anti-Aβ antibody
administration clears intraneuronal Aβ pathology from the hippocampus. Low-magnification photomicrograph of the hippocampus of a PBS-
injected (A) and an anti-Aβ antibody-injected (B) mouse. Note the reduction in intracellular Aβ pathology in the antibody-treated hippocampus
as compared to the PBS-treated hippocampus. (C) i.c.v. anti-Aβ antibody administration decreases intraneuronal Aβ pathology by 86% in the
7 day postinjection group. Quantification of intraneuronal Aβ pathology, shown as the percent decrease in hippocampal Aβ staining in mice
receiving the anti-Aβ treatment as compared to PBS-injected controls. In mice receiving the anti-Aβ antibody 7 days prior to behavior training
and testing, the pathology was decreased by 86%. Thirty days postinjection, the pathology has returned and is not significantly different
from that of PBS-injected tissue. This is a quantification of photomicrographs such as those shown in 5A, 5B, and 5J. Error bars indicate
SEM. (D and E) Differences in Aβ levels following PBS or antibody injection were not due to differences in full-length APP levels. High-
magnification images of the CA1 region of PBS-treated (D) and 1560-treated (E) hippocampi stained with the APP-specific antibody 22C11.
(F and G) Aβ42 is cleared following anti-Aβ antibody injection. Although no Aβ40 staining is apparent in the brains of 4-month-old 3xTg-AD
mice, Aβ42 is present and is cleared following the anti-Aβ immunotherapy. (F) and (G) show high-magnification images of the hippocampus
immunostained with an Aβ42-specific antibody after i.c.v. administration of either PBS (F) or the anti-Aβ antibody (G). (H and I) Intraneuronal
Aβ pathology is not cleared from the amygdala. i.c.v. administration of 1560 into the third ventricle did not clear intraneuronal Aβ pathology
in the amygdala, as there were no differences in Aβ staining between PBS-treated (H) and 1560-treated (I) tissue. (J) Intraneuronal Aβ
pathology returns by 30 days. In mice trained and tested 30 days post-Aβ antibody injection, intraneuronal Aβ returns and is indistinguishable
from PBS-injected (A) or uninjected (Figure 4H) tissue.Cognitive Deficits Retrogress with the Reemergence t
3of Intraneuronal A Neuropathology
As it is possible to rescue the cognitive deficits by re- o
nmoving intraneuronal Aβ pathology, we next deter-
mined whether the return of this pathology is again as- t
usociated with cognitive impairments. Toward this end,
a separate group of 3xTg-AD mice were given an i.c.v. a
injection of the anti-Aβ antibody and tested on MWM
and IA 1 month later, an interval known to allow for the p
dreturn of the intraneuronal Aβ pathology (Oddo et al.,
2004). In these mice, although cannula tract location m
oindicated that the injection was indeed into the ventri-
cle, Aβ immunoreactivity was identical that of to PBS- w
Ainjected 3xTg-AD mice (Figures 5C and 5J), confirming
that the pathology reemerges during this interval. Fur- rhermore, confocal images of hippocampal tissue from
0 day 3xTg-AD mice indicated that the reappearance
f the Aβ pathology is again confined entirely to the
euron, as there was no extracellular Aβ deposition de-
ected by detailed confocal analysis of the images (Fig-
re 6D). No cytoplasmic Aβ staining was apparent in
ge-matched NonTg mice (Figure 6E).
The 3xTg-AD mice receiving the antibody 30 days
rior to training and testing demonstrated retention
eficits identical to those seen in PBS-treated 3xTg-AD
ice (Figures 7B–7D), indicating that, when the pathol-
gy has returned, the cognitive deficits retrogress as
ell. These findings also clearly implicate intraneuronal
β as the cause of the retention deficits: when intraneu-
onal Aβ is allowed to reemerge, it is associated with
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683Figure 6. Detergent-Insoluble Aβ42 Increases
Significantly by 4 Months of Age in the 3xTg-
AD Mice
(A) Detergent-insoluble Aβ42 is significantly
increased in 3xTg-AD-H mice at 4 and 6
months of age. Although detergent-soluble
Aβ40 and Aβ42 do not change between 2 and
6 months of age in the 3xTg-AD–H mice, de-
tergent-insoluble Aβ42, the form of Aβ that
readily forms aggregates, increases signifi-
cantly by 4 months of age. Asterisks indicate
p < 0.05. Error bars indicate SEM.
(B–E) Intraneuronal Aβ is markedly cleared 7
days following Aβ immunotherapy and re-
emerges after 30 days. In PBS-treated 3xTg-
AD mice, there was no clearance of Aβ from
neurons, and careful confocal analysis indi-
cates that this pathology was contained en-
tirely within neurons. However, 7 days after
anti-Aβ antibody administration, 3xTg-AD
mice had almost a complete clearance of in-
traneuronal Aβ (B). Thirty days after antibody
treatment, the pathology within neurons had
returned and consisted of diffuse Aβ immu-
noreactivity within neurons, with no detecta-
ble extracellular Aβ accumulation (D). No Aβ
staining is apparent in NonTg mice (E). Mag-
nification, 100×.the same pattern of long-term retention deficits ob-
served in mice given PBS (Figure 7) or untreated
4-month-old 3xTg-AD mice (Figure 4).
Discussion
Cognitive Deficits Are Age Related
The onset of cognitive decline is a difficult event to
measure in humans, particularly without a reliable bio-
marker. The use of transgenic mouse models to ad-
dress this question is particularly useful, as the early
cognitive changes can be readily identified and corre-
lated with molecular and cellular changes. Here we pro-
vide, to our knowledge, the first evidence to indicate
that intraneuronal Aβ accumulation is the trigger for the
onset of cognitive decline in a transgenic mouse model
of AD.
At 2 months of age, there is no Aβ or tau pathology
present in the 3xTg-AD mice. Electrophysiological mea-
sures, including basal transmission, LTP, and paired-
pulse facilitation appear normal in young, prepatho-
logic mice (Oddo et al., 2003). Likewise, here we report
that young 3xTg-AD mice show normal spatial refer-
ence and contextual fear memory. Therefore, the 3xTg-
AD mice are not born with any deficits in learning and
memory, and any deficits that become apparent must
emerge as a function of age.
Notably, the first cognitive impairment to develop is
a retention, not learning, deficit. These deficits emerge
at 4 months of age and manifest as subtle impairments
in long-term memory. At this age, 3xTg-AD-H mice
show daily learning curves that are indistinguishablefrom those of NonTg or 3xTg-AD hemizygous mice, and
it is only when the acquisition of the spatial MWM task
is analyzed on a per trial basis that the retention deficits
are apparent. In probe trials, 3xTg-AD mice show intact
short-term but impaired long-term memory. A subse-
quent deterioration in memory, including the onset of
short-term memory impairment, is apparent at 6 months
of age, when homozygous mice also show a profound
deficit in LTP and paired-pulse facilitation (Oddo et al.,
2003). Our findings show that the first cognitive deficits
to emerge in the 3xTg-AD mice are impairments in
long-term memory, with subsequent development of
short-term memory impairments as well. The transition
from retention deficits alone to deficits in both short-
and long-term memory indicates a potential stepwise
progression of memory deficits that may be directly re-
lated to the emerging neuropathology. At 4 months of
age, the 3xTg-AD mice develop only intraneuronal Aβ
pathology, with intraneuronal Aβ pathology worsening,
and extracellular deposition beginning, by 6 months of
age. The continued accumulation of Aβ intracellularly is
likely to account for the continued decline of the cogni-
tive phenotype to include short-term, as well as long-
term, memory deficits. In addition, the progression of
the pathology from only intraneuronal Aβ to extracellu-
lar deposition may, in part, explain the exacerbation of
the cognitive deficits.
Interestingly, the subtle, early deficits in long-term
memory apparent in 4-month-old 3xTg-AD mice may
provide an animal model for the early stages of cogni-
tive decline in humans, termed mild cognitive impair-
ment (MCI). Clinically, MCI is considered a transitional
stage prior to the development of AD, but during which
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tention Deficits in 3xTg-AD Mice
Intraneuronal Aβ is cleared from the hippo-
campus and rescues spatial retention defi-
cits. However, in agreement with the lack of
clearance of intraneuronal Aβ in the amyg-
dala, amygdala-dependent contextual fear
deficits are not reversed. (A and B) Aβ immu-
notherapy rescues retention deficits during
acquisition. Acquisition for a spatial refer-
ence task appears normal for all groups
tested (A), though retention deficits are ap-
parent after trial-by-trial analysis (B). Note
that 3xTg-AD mice treated with anti-Aβ 1560
7 days prior to training (3xTg-AD 1560 7 day)
show no retention deficits between daily
training blocks, whereas 3xTg-AD-H mice
given i.c.v. PBS show significant retention
impairments. 3xTg-AD mice given antibody
30 days prior to training (3xTg-AD 1530 30
day), when the pathology is known to re-
emerge, show marked impairments in long-
term memory. Antibody administration had
no effect on NonTg mice in any of the tasks.
Asterisks indicate p < 0.05; error bars indi-
cate SEM. (C–E) Anti-Aβ antibody admin-
istration rescues retention deficits during
probe trials. Anti-Aβ 1560 administration in
3xTg-AD 1560 7 day mice also rescues the
24 hr probe trial retention deficits (C and D).
In contrast, PBS-treated 3xTg-AD mice and
3xTg-AD 1560 30 day mice had increased
latencies to cross platform location (C) and
fewer platform location crosses (D) com-
pared to all other groups. No differences
among groups were noted on the time spent
in the opposite quadrant, again indicating
that 3xTg-AD mice (in this case PBS-treated
or 30 day antibody-treated) show retention
for general but not specific spatial reference
memory. (F) No differences were noted
among groups for acquisition of the cued
MWM task. (G) IA deficits are not rescued by i.c.v. administration of the anti-Aβ antibody. Notably, contextual fear deficits were not rescued
by the Aβ immunotherapy, and nor was the pathology cleared (cf. Figure 5).memory impairments occur with the preservation of t
aother cognitive domains (Grundman et al., 2004). Tradi-
tionally, deficits in declarative memory, such as word a
olist recall, are most affected, with delayed recall being
more affected than immediate recall (Grundman et al., P
a2004), mirroring the early deficits in long-term memory
described here. Studies have suggested that spatial m
alearning in MCI individuals is sensitive to the early
stages in AD, indicating vulnerability of medial temporal w
dlobe structures in humans similar to the early pathology
apparent in the 3xTg-AD mice (Swainson et al., 2001; p
sBlackwell et al., 2004).
The molecular mechanisms that trigger dementia l
esymptoms (which presumably begin prior to or during
MCI manifestation) have been highly elusive. Though d
mmany researchers have sought correlations between
the likely suspects (Aβ, tau) and cognition, the extent c
cof their involvement and whether they underlie the
emergence of early cognitive decline remain unknown. t
pNo clear relationship emerges between Aβ pathology
and cognition in humans with AD, and previous studies a
cwith transgenic mouse models of AD indicate that cog-
nitive impairments manifest prior to overt plaque pa- mhology (Mucke et al., 1994; Hsiao, 1995; Moechars et
l., 1999; Dodart et al., 2002). Our findings indicate that
n earlier event, perhaps an earlier form of Aβ pathol-
gy, may be responsible. Immunization studies in
DAPP and APP+PS1 mice have demonstrated that
nti-Aβ treatment rescues memory deficits without
arked reductions in the Aβ plaque burden (Janus et
l., 2000; Morgan et al., 2000; Dodart et al., 2002),
hich implies that the extensive extracellular Aβ bur-
en in these mice is not solely responsible for the ex-
ression of cognitive deficits. Indeed, although some
tudies have found a relationship between Aβ plaque
oad and learning (Chen et al., 2000) or memory (Hsiao
t al., 1996), neither of these studies has been able to
etermine the biomarker that triggers the onset of early
emory deficits. Chen et al. (2000) reported that in-
reased Aβ plaque deposition is associated with defi-
its in spatial learning. Because our findings suggest
hat memory deficits precede learning deficits, it is ap-
arent that the emergence of subtle memory deficits is
n earlier event than plaque-associated learning defi-
its, and these early changes are caused by the accu-
ulation of Aβ within neurons. Indeed, our studies indi-
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685cate that the removal of intraneuronal Aβ, which
precedes plaque formation, is sufficient to rescue early
cognitive deficits.
Intraneuronal A as a Potential Biomarker
for the Onset of AD
Several studies have implicated intraneuronal Aβ in the
toxic processes in AD (for review, see Tseng et al.,
2004). Cytoplasmic Aβ may be generated under consti-
tutive conditions (Wertkin et al., 1993), and FAD muta-
tions in APP and in PS1 also result in increased intra-
neuronal Aβ42 but not Aβ40 (Martin et al., 1995; Qi et al.,
2003). By using different techniques, including trans-
genic overexpression of intracellular Aβ1-42 and induc-
ible expression of Aβ42 in neuronal cultures, studies
have demonstrated that intraneuronal Aβ42 is cytotoxic
(LaFerla et al., 1995; Magrane et al., 2004). Furthermore,
whereas extracellular application of Aβ40 or Aβ42 to hu-
man primary neurons has no effect on cell viability, di-
rect microinjection of Aβ42 but not Aβ40 causes cytotox-
icity (Zhang et al., 2002). The toxicity of intraneuronal
Aβ42 is particularly relevant in light of recent findings
with human AD brain tissue. Mochizuki et al. found Aβ42
immunoreactivity within neurons that were either close
to or within extracellular plaques (Mochizuki et al.,
2000). Furthermore, Gouras et al. found Aβ42 staining
within hippocampal pyramidal neurons of individuals
with clinical diagnoses ranging from MCI to severe cog-
nitive impairment as determined by the Clinical Demen-
tia Rating Scale (Gouras et al., 2000), indicating that
intraneuronal Aβ accumulation is an early event in hu-
mans with AD as well and is associated with dementia
symptoms. Similar studies from Down’s syndrome pa-
tients provide further corroborating evidence (Gyure et
al., 2001; Mori et al., 2002). The 3xTg-AD mice develop
specific intracellular accumulation of Aβ42, and we
report here that this pathology is cleared with i.c.v. ad-
ministration of an anti-Aβ antibody and that its clear-
ance rescues the retention deficits seen in young 3xTg-
AD mice.
The intraneuronal accumulation of Aβ may have par-
ticularly important implications for signaling involved in
the establishment of learning and memory. A recent
study with APP+PS1 transgenic mice found that imme-
diate-early genes relevant to learning and memory,
such as Zif268, Nurr77, and Arc, are downregulated in
areas of extracellular Aβ accumulation (Dickey et al.,
2004). Because in the 3xTg-AD mice extracellular Aβ
deposition develops following, and in areas overlap-
ping, intraneuronal accumulation, the downregulation
of plasticity-associated immediate-early genes in the
APP+PS1 mice may be due to disruption in intracellular
signaling induced by intraneuronal accumulation of Aβ,
rather than by extracellular Aβ accumulation. Together
with immediate-early gene studies and studies indicat-
ing that cognitive impairments precede extracellular
plaque formation, our findings provide compelling evi-
dence to implicate intraneuronal Aβ as the trigger for
cognitive impairment.
Interaction between Memory Systems
Many findings support an interaction between hippo-
campal and amygdala systems in learning and memory,namely that the hippocampus can influence fear-asso-
ciated learning and memory and that the amygdala can
modulate spatial learning and memory (Packard et al.,
1994; Packard and Teather, 1998; Roozendaal et al.,
1999). Because of this well-established reciprocal rela-
tionship, and because in the present study the pathol-
ogy in the amygdala remains unaffected by the anti-
body treatment, it may appear paradoxical that spatial
learning and memory are fully rescued in 3xTg-AD
mice. However, several findings indicate that the amyg-
dala is capable of modulating hippocampal- and stria-
tal-dependent learning and memory but that these
types of learning and memory persist even without a
functionally intact amygdala. Intraamygdala treatments
can modulate memory in both spatial and cued MWM
tasks (Packard et al., 1994; Packard and Teather, 1998);
however, inactivation of the amygdala by preretention
lidocaine infusion has no effect on learning or retention
in spatial or cued memory (Packard et al., 1994), nor
do amygdala lesions affect acquisition of spatial water
maze tasks (Sutherland and McDonald, 1990). The role
of the amygdala in hippocampal-driven learning and
memory is arguably a modulatory one and not the site
of the memory storage (for review, see McGaugh et
al., 2002).
Concluding Remarks
The identification of a molecular biomarker that signals
the beginning of cognitive decline in AD remains elu-
sive. Although, on a molecular level, whatever pro-
cesses are underlying the cognitive impairments are
most likely relatively advanced by the time any AD
symptoms emerge, a biomarker that signals a pathol-
ogy that can be effectively treated needs to be highly
predictive and early enough in the disease course to
merit using it as a diagnostic tool. Indeed, our studies
report an early, pathogenic biomarker for the onset of
AD-relevant cognitive deterioration. We cannot rule out
that 4-month-old 3xTg-AD mice harbor minute levels of
extracellular Aβ below the limit of detection that might
contribute to the behavioral deficits. However, given
that the MWM deficits are rescued following the clear-
ance of Aβ from the hippocampus, but that it is not
cleared from the amygdala and the deficits in IA are not
rescued, the data indicate that accumulation of intra-
neuronal Aβ is an important pathogenic trigger for the
onset of memory deficits. It is not clear, however, what
aggregation state or form of intraneuronal Aβ induces
this effect (i.e., monomeric, oligomeric Aβ). Future studies
will examine the cognitive impairments in mice with
extensive plaque, as well as tangle pathology, to iden-
tify the contribution of these lesions to late-stage learn-
ing and memory deficits.
Experimental Procedures
Mice and Surgical Procedures
In this study, 270 mice were used. The mice have been charac-
terized previously (Oddo et al., 2003). Briefly, human APP cDNA
harboring the Swedish mutation (KM670/671NL) and human four-
repeat Tau harboring the P301L mutation were comicroinjected into
single-cell embryos of homozygous PS1M146V knockin mice. The
background of the PS1 knockin mice is a hybrid 129/C57BL6.
NonTg mice used were from the same strain and genetic back-
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686ground as the PS1 knockin mice, but they harbor the endogenous m
twild-type mouse PS1 gene. All founder mice of the 3xTg-AD line
were backcrossed to the parental PS1 knockin mice, and both s
hemizygous and homozygous mice were generated. Because of
the technique used to generate the 3xTg-AD mice, all of the mice i
used in this study are on the same genetic and strain background.
F
Male and female mice were individually housed and kept on a 12
m
hr light:12 hr dark schedule. All mice were given ad libitum access
(




The apparatus used for all water maze tasks was a circular alumi- P
num tank (1.5 m diameter) painted white and filled with water main- o
tained at 26°C–29°C. The maze is located in a room containing s
several simple visual, extramaze cues. To reduce stress, mice were b
placed on the platform in both the hidden and cued versions of the t
task for 10 s prior to the first training trial. m
a
Spatial Reference MWM Training N
Mice were trained to swim to a 14 cm diameter circular clear Plexi- e
glas platform submerged 1.5 cm beneath the surface of the water c
and invisible to the mice while swimming. The platform location u
was selected randomly for each mouse, but was kept constant for u
each individual mouse throughout training. On each trial, the A
mouse was placed into the tank at one of four designated start i
points in a pseudorandom order. Mice were allowed to find and a
escape onto the submerged platform. If a mouse failed to find the t
platform within 60 s, it was manually guided to the platform and
allowed to remain there for 10 s. After this, each mouse was placed
Binto a holding cage under a warming lamp for 25 s until the start of
Ethe next trial. To ensure that memory differences were not due to
slack of task learning, mice were given four trials a day for as many
days as were required to train the 3xTg-AD-H and 3xTg-AD-h mice
to criterion (<20 s mean escape latency before the first probe trial I
was run). To control for overtraining, probe trials were run for each M
group, both as soon as they reached group criterion and after all r
groups had reached criterion. f
Retention of the spatial training was assessed 1.5 hr and again i
24 hr after the last training trial. Both probe trials consisted of a 2
60 s free swim in the pool without the platform. Mice were moni- A
tored by a camera mounted in the ceiling directly above the pool, n
and all trials were stored on videotape for subsequent analysis. (
There were no significant differences between any genotypes in p
the swim speeds. The parameters measured during the probe trial f
included (1) initial latency to cross the platform location, (2) number f
of platform location crosses, and (3) time spent in the quadrant h
opposite to the one containing the platform during training. For the e
6 month training, the target quadrant was changed to avoid “sav- t
ings” from previous water maze experience. Target quadrants var- c
ied between mice within a group to control for potential differences a
in the salience of extramaze cues. h
a
Cued MWM Training h
The cued task training consisted of four consecutive 60 s trials per a
day (40 s ITI) and began the first day after the spatial testing ended.
Each trial consisted of the mouse starting from one of five positions
Calong the side of the water tank. The mouse was given 60 s to find
Fthe visible platform (indicated by a striped flag above the water
nlevel). If the mouse did not mount the platform within the 60 s, it
bwas manually guided to the platform. A group mean of <20 s es-
(cape latency was the required criterion, though all genotypes only
1required 3 days of training (12 trials). After mounting the platform,
athe mouse was immediately removed to a holding cage. The visible
Pplatform was moved to different locations between each trial, so




For IA, testing began with a training trial in which a mouse was i
Splaced in a lighted chamber; when the mouse crossed over to the
dark chamber, it received a mild (0.25 mA/1 s) footshock. This initial s
tlatency to enter the dark (shock) compartment served as the base-
line measure. During the probe trials, 1.5 or 24 hr after training, the couse was again placed in the light compartment, and the latency
o return to the dark compartment (previously associated with
hock) was measured as an index of passive fear avoidance.
.c.v. Anti-A Antibody Administration
our-month-old 3xTg-AD-H (n = 19 final) and NonTg (n = 10 final)
ale and female mice (25–37 g) were anesthetized with avertin
1.3% tribromoethanol, 0.8% amylalcohol, given 0.6 ml/25 g body
eight) and placed in a stereotactic apparatus with a mouse adap-
or (MyNeuroLab, St. Louis, MO). Ten microliters of the anti-Aβ anti-
ody (1560 at 1 mg/ml; Chemicon; 14 3xTg-AD and 5 NonTg) or
BS (5 3xTg-AD and 5 NonTg) was injected into the third ventricle
ver 10 min, through a 33G injector attached to a 10 l Hamilton
yringe (Hamilton Company, Reno, NV). The coordinates from
regma were −2.18 mm posterior, 0 mm lateral, and −2.0 ventral to
he skull (Paxinos and Franklin, 1997). Injections occurred over 10
in, and the cannula was left in place for an additional 5 min to
llow for diffusion. Incisions were closed with Tissumend II (My-
eurolab). (Five additional mice were given the surgery and later
xcluded from analysis due to poor placement of cannula. The suc-
essful surgery rate was 85%.) Mice were kept on a warming pad
ntil they had recovered from anesthesia and were monitored daily
ntil they were sacrificed for tissue processing. All but six 3xTg-
D-H mice were given 7 days to recover postsurgery before behav-
oral testing. The remaining six mice were given an i.c.v. injection
t 3.5 months of age and 30 days to recover postsurgery, at which
ime they were trained and tested on the MWM and IA.
iochemical Analysis
LISA Aβ1-40 and Aβ1-42 were measured using techniques as de-
cribed in Oddo et al. (2005).
mmunohistochemistry
ice were sacrificed by CO2 asphyxiation, and the brains were
apidly removed and fixed for 48 hr in 4% paraformaldehyde. Free-
loating sections (50 µm thick) were processed for free-floating
mmunohistochemistry as previously described (Oddo et al., 2003,
004). The anti-Aβ antibody (6E10), anti-APP antibody (22C11),
β40-specific antibody, or Aβ42-specific antibody was applied over-
ight at 4°C. Sections were developed with diaminobenzidine
DAB; Vector Labs) substrate using the avidin-biotin horseradish
eroxidase system (Vector Labs). Quantification of Aβ was per-
ormed as described in Oddo et al. (2004). Mice were excluded
rom the antibody group analysis (behavior and histology) if they
ad incorrect cannula placement. To obtain the percentage differ-
nce between the antibody- and PBS-treated tissue, we applied
he following formula: [number of pixels in antibody-treated hippo-
ampus (sum of five readings per mouse, which were then
veraged across entire group) − number of pixels in PBS-treated
ippocampus (sum of five readings per mouse, which were then
veraged across entire group)]/number of pixels in PBS-treated
ippocampus (sum of five readings per mouse, which were then
veraged across entire group).
onfocal Microscopy
luorescent immunolabeling followed a standard two-way tech-
ique (primary antibody followed by fluorescent secondary anti-
ody). Tissue was processed as described above, then incubated
1 hr) in fluorescently labeled anti-mouse 2° antibody (Alexa 488;
:200; Molecular Probes Inc., Eugene, OR). Nuclear markers were
dded by incubating the slices in TOTO-13 iodide (Molecular
robes Inc.; 1:200 in PBS) for 20 min. Confocal images were cap-
ured on a MRC 1024 (BioRad, Hercules, CA) confocal system.
tatistics
ehavior scores were analyzed using a multifactor ANOVA includ-
ng genotype, age, and/or probe trial (1.5 hr and 24 hr). Post hoc
cheffe tests determined individual differences in groups with re-
pect to NonTg mice. When indicated, Student’s t tests were used
o determine differences between mice in the longitudinal and
ross-sectional studies. Immunohistochemistry scores were ana-
Intraneuronal Aβ Triggers Cognitive Deficits
687lyzed by ANOVA. Results were considered significant when p <
0.05.
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